Xalkori Uniunea Europeană - română - EMA (European Medicines Agency)

xalkori

pfizer europe ma eeig - crizotinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

XALKORI România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

xalkori

pfizer manufacturing deutschland gmbh - germania - crizotinibum - caps. - 200mg - inhibitori de protein-kinaza

XALKORI România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

xalkori

pfizer manufacturing deutschland gmbh - germania - crizotinibum - caps. - 250 mg - inhibitori de protein-kinaza